N. Santoni, T. Melo, A. R. Aguirre, D. Veiga, e C. Souza, “Cost-effectiveness of afatinib versus pemetrexed plus cisplatin, erlotinib and gefitinib as first line treatment in patients with locally advanced or metastatic epidermal growth factor receptor mutation (EFGR+) non-small cell lung cancer in the Brazil”, JBES, vol. 9, nº 1, p. 73–82, abr. 2017.